Perioperative Management of Apixaban

Preoperative Discontinuation Strategy

• The American College of Chest Physicians recommends discontinuing apixaban 1 day before low-to-moderate bleeding risk procedures and 2 days before high bleeding risk procedures for patients with normal or mildly impaired renal function, with longer interruption periods required for patients with impaired renal function 1
• For patients with normal or mildly impaired renal function, stopping apixaban 1 day before low-to-moderate bleeding risk procedures corresponds to 2-3 half-lives and 3-6% residual anticoagulant effect, while stopping 2 days before high bleeding risk procedures corresponds to 4 half-lives and minimal residual anticoagulant effect 1, 2
• For patients with moderate renal impairment, the recommended discontinuation times are 3 days before low-to-moderate bleeding risk procedures and 4 days before high bleeding risk procedures 3, 4

Defining Bleeding Risk Categories

• High bleeding risk procedures include cardiac surgery, intracranial/spinal surgery, and major abdominal surgery, as defined by the guideline society 2
• Low-to-moderate bleeding risk procedures include arthroscopy, colonoscopy with biopsy, and abdominal hernia repair, as defined by the guideline society 2

Critical Considerations for Renal Impairment

• Patients with severe chronic kidney disease or end-stage kidney disease can accumulate apixaban and experience catastrophic bleeding, including rare sites such as pleural, pericardial, and intracranial hemorrhage 5
• Extended preoperative interruption is essential in patients with declining renal function, even if baseline function was acceptable 5

Postoperative Resumption Strategy

• For low bleeding risk surgery, apixaban can be resumed 24 hours postoperatively at the usual dose, ensuring at least 6 hours have elapsed after the invasive procedure and adequate hemostasis is established 5, 2
• For high bleeding risk surgery, apixaban can be resumed 2-3 days after surgery, with consideration of a reduced dose for the first 2-3 days in patients at high thromboembolism risk 5, 2

Important Postoperative Considerations

• Rapid resumption of apixaban at full therapeutic doses immediately after major surgery should be avoided due to its rapid onset of action, which poses a bleeding risk if hemostasis is incomplete 5, 4
• Factors affecting drug absorption, such as postoperative bowel dysmotility and acid-suppressive therapy, should be accounted for after major abdominal surgery 2

Bridging Anticoagulation

• Bridging with heparin or low molecular weight heparin is not recommended during the perioperative period, as it increases the risk of major bleeding without reducing stroke or systemic embolism 1, 2
• Evidence from the RE-LY trial subanalysis demonstrated that perioperative low molecular weight heparin bridging increased major bleeding risk without reducing stroke or systemic embolism 1

Common Pitfalls and Caveats

• Standard coagulation tests, such as INR and aPTT, are not useful for monitoring apixaban effect, while anti-Xa activity correlates well with apixaban exposure if measurement is needed 1
• Premature resumption of apixaban after high-risk surgery can precipitate major bleeding due to its rapid onset of action 5, 4

Apixaban Interruption for Ultrasound‑Guided Thoracentesis in Severe Renal Impairment

Holding Recommendations

• Patients with severe renal impairment (creatinine clearance < 15 mL/min) should discontinue apixaban at least 72 hours before a low‑to‑moderate bleeding‑risk procedure such as ultrasound‑guided thoracentesis; drug‑specific anti‑Xa level measurement is advised to confirm adequate clearance. – American College of Cardiology recommendation, based on expert consensus. 6

Laboratory Monitoring

• Routine coagulation tests (INR, aPTT) do not reliably reflect apixaban activity for procedural timing; if laboratory assessment is required, anti‑Xa activity provides a more accurate correlation with drug exposure. – American College of Cardiology guidance, derived from pharmacologic evidence. 6

Perioperative Management of Apixaban for High‑Bleeding‑Risk Ocular Surgery

Pre‑operative Discontinuation Based on Renal Function

• Normal or mild renal impairment (CrCl ≥ 50 mL/min): Stop apixaban 2 days (≈48 h) before surgery, skipping four doses; this allows 4–5 half‑lives to elapse, reducing residual anticoagulant effect to roughly 12–25 %【7】.
• Moderate renal impairment (CrCl 30–50 mL/min): Stop apixaban 3 days (≈72 h) before surgery, skipping six doses; the prolonged half‑life (~10–12 h) in this group necessitates the longer interruption【8】.
• Guideline recommendation (American College of Chest Physicians, 2022): For high‑bleeding‑risk procedures in patients with normal renal function, a 2‑day interruption is advised【7】.
• Guideline recommendation (Blood, 2012): A more conservative 2–3‑day interruption is suggested for high‑risk surgeries, which may be preferable for ophthalmic procedures given the catastrophic potential of intra‑ocular hemorrhage【8】.

Bridging Anticoagulation

• Bridging is not recommended: Use of unfractionated heparin or low‑molecular‑weight heparin during the apixaban interruption period should be avoided【7】.
• Rationale: Apixaban’s rapid offset (half‑life 7–8 h) and rapid onset eliminate the need for bridging therapy【7】.

Post‑operative Resumption

• Timing of restart: Resume apixaban at least 24 h after surgery, preferably 48–72 h, once adequate hemostasis is confirmed for high‑bleeding‑risk ocular procedures【7】.
• Pharmacologic consideration: Because apixaban reaches peak effect within 1–3 h, restarting too early can precipitate bleeding; the 48–72 h window provides safety margin【8】.
• Dose and safety check: Restart at the usual therapeutic dose (typically 5 mg twice daily) unless renal function or other factors dictate dose reduction; ensure no active bleeding before the first postoperative dose【7】.

Risks of Deviating from Recommended Timing

• Excessively long interruption: Extending the pre‑operative hold beyond 3–4 days in patients with normal renal function raises thromboembolic risk without additional bleeding protection【7】.
• Renal function assessment: Mandatory calculation of creatinine clearance before determining interruption length, as moderate‑to‑severe impairment significantly prolongs apixaban elimination【8】.

Pre‑operative Management of Apixaban for Colonoscopy

Renal‑function–guided interruption

• In patients with moderate renal impairment (creatinine clearance 30–50 mL/min) undergoing high‑bleeding‑risk colonoscopic procedures such as polypectomy, apixaban should be stopped 72 hours (3 days) before the procedure to allow adequate drug clearance【9】.

Bleeding‑risk classification (British Society of Gastroenterology)

• The British Society of Gastroenterology classifies high‑bleeding‑risk endoscopic interventions as including polypectomy, sphincterotomy, laser therapy, mucosal ablation, and variceal treatment【10】.
• It classifies low‑ to moderate‑bleeding‑risk procedures as diagnostic colonoscopy with biopsy only【10】.

Expected bleeding rates in anticoagulated patients (British Society of Gastroenterology)

• According to the British Society of Gastroenterology, the post‑polypectomy bleeding rate in patients receiving apixaban or other anticoagulants ranges from 14 % to 23 %, which is markedly higher than the 0.07 %–1.7 % observed in non‑anticoagulated patients【10】.